November 7, 2025 — Leads & Copy —
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) will present data from its LIVMARLI (maralixibat) and volixibat clinical programs at The Liver Meeting®, the annual conference of the American Association for the Study of Liver Diseases (AASLD), held November 7-11, 2025, in Washington, D.C.
The presentations highlight Mirum’s work in expanding the scientific and clinical foundation for new approaches to treating adult and pediatric rare liver diseases. They include new findings from the VANTAGE trial and real-world studies.
A key presentation will be an oral presentation of additional analyses from the VANTAGE trial, which evaluates volixibat in adults with primary biliary cholangitis (PBC). Kris Kowdley from Liver Institute Northwest, Seattle, Washington, USA will present Abstract #0215, titled “Volixibat Leads to Improvements in Fatigue and Sleep for Adults with Primary Biliary Cholangitis: Data from VANTAGE Trial,” on Monday, November 10, 2025, from 3:00-3:15 pm during the ‘Novel Therapies and Monitoring in Cholestatic Liver Disease’ session, Room 145, Level 1, Convention Center.
Several poster presentations will also take place highlighting real-world experience with maralixibat and insights from genetic testing in cholestasis.
Dr. Adrielly Martins, University of Miami, Florida, USA will present Abstract #4411, titled “Maralixibat, an Ileal Bile Acid Transporter Inhibitor, Reduces Cholestatic Pruritus in PSC: Real-World Experience,” on Monday, November 10, 2025, from 1:00-2:00 pm at the Posters and Exhibit Hall, Level 2, Convention Center.
Dr. Tiziano Pramparo, Mirum Pharmaceuticals, Inc., Foster City, California, USA, will present Abstract #4412, titled “Clinical Utility of Comprehensive Genetic Testing in Adult Cholestasis: Insights from 856 Panel Tests,” on Monday, November 10, 2025, from 1:00-2:00 pm at the Posters and Exhibit Hall, Level 2, Convention Center.
Dr. Alan Bonder, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA will present Abstract #4415, titled “Exploring the Role of Ileal Bile Acid Transporter Inhibitors, Like Volixibat, in the Regulation of IL-31 and Serum Bile Acids in Patients with Primary Biliary Cholangitis: Preliminary Results from the VANTAGE Trial,” on Monday, November 10, 2025, from 1:00-2:00 pm at the Posters and Exhibit Hall, Level 2, Convention Center.
Dr. Marlyn Mayo, UT Southwestern Medical Center, Dallas, Texas, USA will present Abstract #4511, titled “Physician Reported Assessment of Pruritus Amongst Patients with PSC: Results from a Real-World Survey in France, Germany, Italy and the United States” on Monday, November 10, 2025, from 1:00-2:00 pm at the Posters and Exhibit Hall, Level 2, Convention Center.
Dr. Natasha Dilwali, Columbia University Irving Medical Center, New York, New York, USA will present Abstract #4532, titled “Impact of Maralixibat on Caregiver Burden for Patients with Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis: Baseline and 6-month Follow-up,” on Monday, November 10, 2025, from 1:00-2:00 pm at the Posters and Exhibit Hall, Level 2, Convention Center.
Mirum will also host an educational fireside discussion addressing current approaches to Progressive Familial Intrahepatic Cholestasis (PFIC) diagnosis and management. During The Liver Meeting, Mirum will host a session featuring Dr. Robert Gish, Loma Linda University, focused on the recognition and diagnosis of PFIC, including the role of genetic testing and disease management considerations for adults. The discussion will also include a review of clinical data for LIVMARLI in PFIC. This discussion will take place Sunday, November 9, 2025, 1:30-2:00 pm at the Exhibit Hall TLM Theater.
Full abstracts are available on the AASLD website, and detailed analyses will be posted in the Publications and Presentations section of Mirum’s website following the conference.
Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution/LIVMARLI® (maralixibat) tablets, CHOLBAM® (cholic acid) capsules, and CTEXLI® (chenodiol) tablets.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
Contact:
Erin Alldredge
ir@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.
